Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
ARGX [bullish]
argenx SE
+62.46%
current return
Author Info
No bio for this author
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 540.39
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
PGIM Jennison Health Sciences Fund Portfolio Holding: argenx SE
ARGX: Vyvgart, 1st-in-class anti-FcRn for MG, exceeds expectations. $5B+ peak sales in MG, $4B+ in CIDP. SubQ formulation approved. Pipeline potential with empasiprubart. $2B sales in 2024 to $8B early 2030s. Zai Lab partnership for China. Multiple readouts 2024/25. Lean structure supports high growth.
Read full article (2 min)